JYPC(002198)2022-12-06 02:46Group 1: Company Operations - The management structure of the company is stable, and the operational situation is normal [1] - Tiger Hui is not currently involved in the actual operations of the company, and there are no significant disagreements between the management and Tiger Hui [2] Group 2: Production and Capacity - The company’s subsidiary, Huqingyuan Bio, is expanding the cultivation of the Mei tree as planned, with natural borne ice currently in small-scale trial production [2] - The company is optimistic about the development prospects of the Mei tree industry, believing it will contribute to future performance [2] - The fundraising projects from the IPO, including the production of dual-purpose throat wind powder and solid essence ginseng pills, have been completed, with capacity utilization reaching approximately 100% [2] Group 3: Research and Development - The company’s new drugs, including diabetes and anti-tumor medications, are in different stages of development, with diabetes drugs in clinical stages and anti-tumor drugs in preclinical research [3] - The company will disclose any new developments in drug research in accordance with regulations [3] Group 4: Shareholder Actions - The company acknowledges that shareholders may reduce their holdings for personal financing or lifestyle improvements, complying with legal and regulatory requirements for information disclosure [3]